Can a Four-Drug cocktail outsmart resistant lymphoma?
NCT ID NCT07774234
First seen Aug 19, 2026 · Last updated Aug 19, 2026
Summary
This phase II trial is testing whether a combination of four drugs—sonrotoclax, glofitamab, gemcitabine, and oxaliplatin—can shrink or eliminate tumors in adults with large B-cell lymphoma that has returned or not responded to previous treatment. Participants will receive the drugs in 21-day cycles, with the main goal of measuring how many achieve a complete response after six cycles. The study aims to enroll 39 people and will also track safety and how long any benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of four drugs: sonrotoclax (oral), glofitamab (intravenous), gemcitabine (intravenous), and oxaliplatin (intravenous)
- What this could lead to
- If this combination works, it could offer a new treatment option for people with large B-cell lymphoma that has come back or stopped responding to prior therapy.
- What could go wrong
- This is a small, early-phase study, so the treatment may not be effective for everyone and could cause significant side effects. The results will need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE-HIT OR TRIPLE-HIT LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out
- Can a single shot build a cancer army inside the body?
- AI takes on lymphoma: personalized drug cocktail aims to outsmart cancer in older patients
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients